Improvement of Liver Function by a Short-term Administration of Luseogliflozin in Patients with Type 2 Diabetes: A Single-arm Study and the Mini-literature Review


 

Abstract

Background: Non-alcoholic fatty liver disease is not simply the hepatic manifestation of obesity and diabetes but also linked to hepatocellular carcinoma. Yet, its effective treatment has not been established. In this study, we evaluated the effect of a short-term administration of luseogliflozin to patients with type 2 diabetes having non-alcohol fatty liver disease. Luseogliflozin is a unique sodium-glucose cotransporter 2 inhibitor which is metabolized in and excreted by the liver in addition to the kidney. Therefore, the drug might possess an additional effect on other agents of the same class which are exclusively metabolized in the kidney.

Methods: Using alanine aminotransferase >20 IU/L as a diagnostic basis for non-alcoholic fatty liver disease, 19 patients, not taking alcohol, with type 2 diabetes (male/female 15/4, the median age 57 years) was treated with 2.5 mg luseogliflozin for 12 weeks.

Results: Pre- and post-treatment median values for alanine aminotransferase were 51 IU/L and 33 IU/L (p = 0.001), and the corresponding values for the fibrosis index based on the four factors [age (years) ∙ alanine aminotransferase (IU/L)] / [platelets (109/L) ∙ alanine aminotransferase (IU/L)1/2)] were 1.669 and 1.314 (p = 0.043). There was no adverse effect of the drug. Our findings were essentially compatible with the results of the previous studies reviewed.

Conclusion: We conclude that sodium-glucose cotransporter 2 inhibitor could be the choice for the pharmacological treatment of non-alcoholic fatty liver disease. Especially, a short-term administration of it is consistently effective in mild cases.

 

Read more about this article: https://lupinepublishers.com/gastroenterology-hepatology-journal/fulltext/improvement-of-liver-function-by-a-short-term-administration-of-luseogliflozin-in-patients-with-type-2-diabetes-a-single-arm-study-and-the-mini-literature-review.ID.000156.php

 Read more about Lupine Publishers Google Scholar articles: https://scholar.google.com/citations?view_op=view_citation&hl=en&user=XbnlB50AAAAJ&cstart=400&pagesize=100&citation_for_view=XbnlB50AAAAJ:AFXcoJnoRH0C

Comments

Post a Comment

Popular posts from this blog

Lupine Publishers-Journal of Clinical Gastroenterology and Hepatology

Image
Portal Hypertensive Gastric Polyps by Umadevi Malladi in Current Trends in Gastroenterologyand Hepatology in Lupine Publishers Portal hypertension is associated with an increased number of gastric polyps, hence the term portal hypertension-associated gastric polyps. Histopathological examination reveals mucosal hyperplasia and vascular proliferation. Formation may be due to mucosal injury that is vascular in nature. Their malignant potential has not been fully elucidated; however, lesions can grow to a large size. Patients with portal hypertension are at increased risk of post polypectomy bleeding and other complications of polypectomy. Surveillance is likely to be safer than multiple polypectomies, therefore in patients with portal hypertension it is essential that gastric polyps are photographed and biopsied during routine surveillance gastroscopies.  https://lupinepublishers.com/gastroenterology-hepatology-journal/fulltext/portal-hypertensive-gastric-polyps.ID.000...
Read more

Lupine Publishers - Journals of Gastroenterology and Hepatology

Image
The Current Approach to the Hepatocellular Carcinoma; AMini Review of Etiology, Prognosis and Treatment by Nuri Emrah Göret in Current Trends in Gastroenterology and Hepatology - Lupine Publishers   Abstract Hepatocellular carcinoma (HCC) is the most common liver malignancy worldwide and is one of the major causes of cancerrelated deaths. HCC is reported to be the second most fatal malignancy. The major risk factors for HCC are well known; the known risk factors include hepatitis C virus (HCV) and hepatitis B virus (HBV). Major advances have been reported in the treatment of HCC. Success of early diagnosis increases when these risk factors are identified, and the cases are followed up. It is reported that in the treatment of early-diagnosed HCC cases, ethanol injection or radiofrequency ablation methods as well as surgical resection should be preferred, particularly in cases without liver cirrhosis and in cases where the tumor is restricted. Similarly, l...
Read more

Lupine Publishers-Gastroenterology open access journal

Image
Fungal Infections in Gastroenterology by Michael AB Naafs MD in Current Trends in Gastroenterology and Hepatology in Lupine Publishers Fungal infections are increasing in gastroenterology. Cirrhotic patients, liver transplantation recipients, and patients with inflammatory bowel disease (IBD) are vulnerable to these infections. The origin of these fungal infections is frequently the GI tract. The advent of sequencing technology can identify now previously unculturable fungi. Dysbiosis of the mycobiome and microbiome can uncheck normal commensal fungi and turn pathogenic by largely unknown mechanisms Resistance to antifungals is becoming a global problem. New antifungals are in development and they are badly needed. In this mini-review the enteric mycobiota and fungal infections in GI disease are discussed https://lupinepublishers.com/gastroenterology-hepatology-journal/fulltext/fungal-infections-in-gastroenterology.ID.000114.php ht...
Read more